TY - JOUR
TI - Interpreting the results of the VERTIS-CV trial: Is this the end of the “class effect” perspective? [解读VERTIS-CV试验的结果:这是“类效应”视角的终结吗?]
AU - Koufakis, T.
AU - Papanas, N.
AU - Dimitriadis, G.
AU - Zebekakis, P.
AU - Kotsa, K.
JO - WORLD JOURNAL OF DIABETES
PY - 2020
VL - 12
TODO - 12
SP - 942-945
PB - John Wiley and Sons Inc
SN - null
TODO - 10.1111/1753-0407.13105
TODO - ertugliflozin;  hemoglobin A1c;  ertugliflozin;  fused heterocyclic rings;  glycosylated hemoglobin, all cause mortality;  body mass;  drug efficacy;  drug safety;  drug screening;  estimated glomerular filtration rate;  hemoglobin blood level;  hospital admission;  hospitalization;  human;  incidence;  non insulin dependent diabetes mellitus;  Note;  priority journal;  randomized controlled trial (topic);  treatment outcome;  trend study;  aged;  blood;  cardiovascular disease;  clinical trial;  controlled study;  follow up;  glucose blood level;  metabolism;  middle aged;  non insulin dependent diabetes mellitus;  phase 3 clinical trial;  procedures;  randomized controlled trial, Aged;  Blood Glucose;  Bridged Bicyclo Compounds, Heterocyclic;  Cardiovascular Diseases;  Diabetes Mellitus, Type 2;  Follow-Up Studies;  Glycated Hemoglobin A;  Humans;  Middle Aged;  Outcome Assessment, Health Care;  Sodium-Glucose Transporter 2 Inhibitors
TODO - null
ER -